What question did this study set out to answer?

To review the clinical efficacy, safety profile, and therapeutic role of pertuzumab in the treatment of HER2-positive breast cancer across early and advanced disease settings.

October 1, 2019Core evidenceOpen Access

Pertuzumab in the treatment of HER2-positive breast cancer: an evidence-based review of its safety, efficacy, and place in therapy

View Full Paper

Ask AI

Bookmark

Authors

KIKei IshiiKyoto University NMNao MoriiTenri Hospital HYHiroyasu YamashiroTenri Hospital

Discussion

Member takes

Implication

Evidence-based review demonstrates dual HER2 blockade with pertuzumab improves breast cancer outcomes with low cardiac toxicity, highlighting the need for selective patient targeting.

Key Points

To review the clinical efficacy, safety profile, and therapeutic role of pertuzumab in the treatment of HER2-positive breast cancer across early and advanced disease settings.
Synthesized evidence from key clinical trials evaluating pertuzumab, including the CLEOPATRA, APHINITY, NeoSphere, and TRYPHAENA trials.
Assessed outcomes of dual HER2 blockade using pertuzumab combined with trastuzumab and various chemotherapy regimens in palliative, adjuvant, and neoadjuvant contexts.
Pertuzumab combined with trastuzumab demonstrated clinical efficacy and safety across early, locally advanced, and metastatic HER2-positive disease regardless of patient age or hormone receptor status.
Pertuzumab exhibited a favorable safety profile with a low risk of treatment-induced cardiac dysfunction, while non-severe diarrhea represented the most frequent adverse event.
Subgroup and pharmacoeconomic analyses revealed minimal clinical benefit in patients with node-negative disease or small primary tumors alongside poor cost-effectiveness.

Cite This Study

Ishii et al. (2019) studied this question.

synapsesocial.com/papers/6a18dd27c9d74cf65281fb9b https://doi.org/10.2147/ce.s217848

View Full Paper

Ask AI

Bookmark

Implication

Evidence-based review demonstrates dual HER2 blockade with pertuzumab improves breast cancer outcomes with low cardiac toxicity, highlighting the need for selective patient targeting.

Pertuzumab in the treatment of HER2-positive breast cancer: an evidence-based review of its safety, efficacy, and place in therapy

Discussion

Member takes

Implication

Key Points

Cite This Study

Pertuzumab in the treatment of HER2-positive breast cancer: an evidence-based review of its safety, efficacy, and place in therapy

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider